Miao, Beiping, Hu, Zhaoqing, Mezzadra, Riccardo, Hoeijmakers, Lotte, Fauster, Astrid, Du, Shangce, Yang, Zhi, Sator-Schmitt, Melanie, Engel, Helena, Li, Xueshen, Broderick, Caroline, Jin, Guangzhi, Gomez-Eerland, Raquel, Rozeman, Lisette, Lei, Xin, Matsuo, Hitoshi, Yang, Chen, Hofland, Ingrid, Peters, Dennis, and Broeks, Annegien
The dysregulated expression of immune checkpoint molecules enables cancer cells to evade immune destruction. While blockade of inhibitory immune checkpoints like PD-L1 forms the basis of current cancer immunotherapies, a deficiency in costimulatory signals can render these therapies futile. CD58, a costimulatory ligand, plays a crucial role in antitumor immune responses, but the mechanisms controlling its expression remain unclear. Using two systematic approaches, we reveal that CMTM6 positively regulates CD58 expression. Notably, CMTM6 interacts with both CD58 and PD-L1, maintaining the expression of these two immune checkpoint ligands with opposing functions. Functionally, the presence of CMTM6 and CD58 on tumor cells significantly affects T cell-tumor interactions and response to PD-L1−PD-1 blockade. Collectively, these findings provide fundamental insights into CD58 regulation, uncover a shared regulator of stimulatory and inhibitory immune checkpoints, and highlight the importance of tumor-intrinsic CMTM6 and CD58 expression in antitumor immune responses. [Display omitted] • CMTM6 maintains the expression of CD58 • CMTM6 co-regulates and interacts with both CD58 and PD-L1 • Tumor cell-intrinsic CMTM6 and CD58 are important for antitumor T cell response Miao et al. reveal CMTM6 as a positive regulator and interaction partner of CD58, an important costimulatory ligand in antitumor immune responses. They highlight the critical roles of tumor-intrinsic CMTM6 and CD58 expression in modulating T cell-tumor cell interactions and their potential impact on T cell-based immunotherapy. [ABSTRACT FROM AUTHOR]